CELGENE: OTEZLA (apremilast) , an inhibitor of phosphodieasterase 4 (PDE4), is indicated for the treatment of adult patients with active psoriatic arthritis . PALADIN THERAPEUTICS INC: IMPAVIDO (MILTEFOSINE) is an antileishmanial drug indicated in adults and adolescents ≥12 years of age weighing ≥30 kg (66 lbs) for treatment of: 1)Visceral leishmaniasis due to Leishmania donovani. 2) Cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis. 3) Mucosal leishmaniasis due to Leishmania braziliensis. PIRAMAL IMAGING: Neuraceq™ (FLORBETABEN) is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations. New dosage form of AVEED from ENDO PHARMS, XARTEMIS XR from MALLINCKRODT INC, QUDEXY XR from UPSHER SMITH LABS, DOCETAXEL from PFIZER, and NOXAFIL from MERCK SHARP DOHME were approved. In addition, new formulation or new manufacturer for HEMANGEOL from PIERRE FABRE, and METRONIDAZOLE from VALEANT PHARMS were approved.

1. PharmaSages_March FDA Approvals
CELGENE: OTEZLA (apremilast) , an inhibitor of phosphodieasterase 4 (PDE4), is indicated
for the treatment of adult patients with active psoriatic arthritis .
PALADIN THERAPEUTICS INC: IMPAVIDO (MILTEFOSINE) is an antileishmanial drug
indicated in adults and adolescents ≥12 years of age weighing ≥30 kg (66 lbs) for treatment
of: 1)Visceral leishmaniasis due to Leishmania donovani. 2) Cutaneous leishmaniasis due to
Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis. 3) Mucosal
leishmaniasis due to Leishmania braziliensis.
PIRAMAL IMAGING: Neuraceq™ (FLORBETABEN) is a radioactive diagnostic agent
indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-
amyloid neuritic plaque density in adult patients with cognitive impairment who are being
evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative
Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a
neuropathological diagnosis of AD at the time of image acquisition; a negative scan result
reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive
Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological
examination has shown this amount of amyloid neuritic plaque is present in patients with
AD, but may also be present in patients with other types of neurologic conditions as well as
older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.
New dosage form of AVEED from ENDO PHARMS, XARTEMIS XR from MALLINCKRODT INC, QUDEXY XR from UPSHER
SMITH LABS, DOCETAXEL from PFIZER, and NOXAFIL from MERCK SHARP DOHME were approved.
In addition, new formulation or new manufacturer for HEMANGEOL from PIERRE FABRE, and METRONIDAZOLE from
VALEANT PHARMS were approved.

2. Contact us
Ajay Shrivastava, CEO
PharmaSages
58 Magnolia Lane
Princeton, NJ 08540
Phone: (609)423-7602
E-mail:asbiopro@pharmasages.com
Web: www.pharmasages.com